Dupilumab, a monoclonal antibody targeting the α subunit of the Interleukin-4 Receptor (IL-4Rα), blocks IL-4 and IL-13 signaling and has been proposed as a potential treatment for localized scleroderma.2 The gene discussed is IL4R; the disease is localized scleroderma.